Sign in

You're signed outSign in or to get full access.

OM

Orthofix Medical Inc. (OFIX)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 delivered solid top-line and profitability momentum: reported revenue $205.6M and pro forma net sales $203.4M grew 4.6% and 6.3% YoY (5.7% constant currency), with seventh straight quarter of adjusted EBITDA margin expansion; free cash flow was +$2.5M .
  • Results exceeded S&P Global consensus: revenue $205.6M vs $200.0M estimate (+$5.6M beat); Primary EPS $0.20 vs (-$0.41) estimate (meaningful beat). Note: S&P GAAP EBITDA actual (-$2.7M) vs $20.2M consensus reflects large non‑GAAP add-backs (e.g., litigation) that underpin company’s adjusted EBITDA of $25.1M .
  • Guidance: FY25 pro forma net sales narrowed to $810–$814M (midpoint unchanged), pro forma adjusted EBITDA raised to $84–$86M (up from $82–$86M), and FCF guide maintained positive .
  • Key drivers/catalysts: U.S. Spine Fixation +8% net sales and +10% procedures (7D FLASH navigation pull‑through, distributor transitions), U.S. Orthopedics +19% (TrueLok Elevate), BGT +6% . CFO indicated Q4 growth comp headwind vs a strong prior-year quarter, tempering sequential acceleration .

What Went Well and What Went Wrong

What Went Well

  • U.S. Spine momentum: U.S. Spine Fixation net sales +8% YoY and procedures +10%; management credits 7D FLASH navigation pull‑through and distributor transitions .
  • Orthopedics & BGT outperformance: U.S. Orthopedics +19% on TrueLok Elevate launch; Bone Growth Therapies +6% YoY, with fracture channel strength .
  • Profitability/FCF traction: Pro forma adjusted EBITDA $24.6M (+28% YoY) with ~233 bps margin expansion; seventh straight quarter of adjusted EBITDA margin improvement; FCF +$2.5M .

What Went Wrong

  • GAAP loss persisted: GAAP net loss of $(22.8)M (–$0.57/sh) despite adj. profitability, driven in part by $21.5M litigation/investigation costs .
  • Mix/price headwinds: CFO cited a price decrease at a major account and unfavorable geography mix (higher international spine/biologics) as gross margin offsets .
  • Sequential liquidity dip: Cash, cash equivalents and restricted cash ended at $65.9M (vs $68.7M at 6/30/25) as the company forward-placed some inventory to support 2026 start .

Financial Results

Core P&L and Margins

MetricQ3 2024Q2 2025Q3 2025
Reported Revenue ($M)196.6 203.1 205.6
Pro forma Net Sales ($M)191.3 200.7 203.4
GAAP Diluted EPS ($)-0.71 -0.36 -0.57
Adjusted EBITDA ($M)19.18 20.94 25.11
Pro forma Adjusted EBITDA ($M)17.52 20.65 24.58
Pro forma Adjusted Gross Margin (%)72.0% 72.7% 72.1%

S&P Global Consensus vs Actual (Q3 2025)

MetricConsensus (S&P)*ActualSurprise
Revenue ($M)200.0*205.6 +$5.6M
Primary EPS ($)-0.407*0.198*+$0.605
EBITDA ($M)20.19*-2.65*-$22.84M

Values retrieved from S&P Global.*

Segment Performance (pro forma; excludes M6)

Segment ($M)Q3 2024Q3 2025YoY (cc)
Bone Growth Therapies57.9 61.2 5.7%
Spinal Implants, Biologics & Enabling Tech102.9 108.6 5.6%
Global Spine (total)160.8 169.8 5.6%
Global Orthopedics30.5 33.6 5.9% (10.1% rpt)
Pro forma Net Sales191.3 203.4 5.7% (6.3% rpt)
Impact from M6 discontinuation5.3 2.2 (58.6%)
Reported Revenue196.6 205.6 3.9% (4.6% rpt)

KPIs and Cash

KPIQ2 2025Q3 2025
U.S. Spine Fixation net sales growth YoY+5% +8%
U.S. Spine Fixation procedure growth YoY+7% +10%
U.S. Orthopedics net sales growth YoY+28% +19%
BGT net sales growth YoY+6% +6%
GAAP Gross Margin (%)68.7% 72.2%
Pro forma Adjusted Gross Margin (%)72.7% 72.1%
Free Cash Flow ($M)4.5 2.5
Cash + Restricted Cash ($M)68.7 (as of 6/30/25) 65.9 (as of 9/30/25)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Pro forma Net SalesFY 2025$808–$816M $810–$814M Narrowed (midpoint maintained)
Pro forma Adjusted EBITDAFY 2025$82–$86M $84–$86M Raised low end
Free Cash FlowFY 2025Positive (ex‑M6 restructuring) Positive (ex‑M6 restructuring) Maintained
Gross Margin2H 2025—≈72% (CFO commentary) New color
Stock‑based compFY 2025—~$28–$29M New color
D&A (adjusted)FY 2025—≈$38M New color
Interest & other expensePer quarter—≈$5M/quarter New color

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1–Q2 2025)Current Period (Q3 2025)Trend
7D FLASH navigation and pull‑throughEmphasized as core differentiator and cross‑portfolio driver; deployments up; earn‑out model highlighted Continued adoption; U.S. 7D placements up YTD; Voyager earn‑out customers exceeding commitments by >50% on average Improving
Distributor transitions (U.S. Spine)Plan to optimize channel and consolidate/expand where needed; early traction Top 30 U.S. distributor partners +25% YoY in Q3; +33% TTM; transitions cited as growth catalyst Improving
Product launchesQ2: TrueLok Elevate global launch; Reef L U.S. launch; Virata limited launch Q3: TrueLok Elevate full commercial launch driving U.S. Ortho +19%; Virata limited release progressing, full launch expected 2H26 Improving
Gross margin and mixQ1–Q2 pro forma adj GM 70.3–72.7%; productivity initiatives noted Pro forma adj GM 72.1%; improvement from M6 discontinuation and productivity, partially offset by unfavorable geography mix Stable to improving
BGT executionAbove‑market growth; cross‑selling momentum +6% YoY; fracture channel outperforming Stable
Legal/litigation costsOngoing legal/investigation items noted $21.5M litigation/investigation expense added back to adjusted results Ongoing headwind
Free cash flowTarget positive FY25; Q2 FCF +$4.5M Q3 FCF +$2.5M; expect 2H positive; Q4 not as strong as LY due to inventory placement Improving (near‑term planned build)

Management Commentary

  • CEO on growth drivers: “Our U.S. Spine Fixation segment outpaced market growth, fueled by the unique advantages of our 7D FLASH navigation technology… [and] positive impact of recent distributor transitions.”
  • CEO on Orthopedics: “The full commercial launch of TrueLok Elevate is off to a promising start… deliver meaningful value to both patients and providers.”
  • CEO on profitability focus: “Seventh consecutive quarter of adjusted EBITDA margin expansion and sustained positive free cash flow generation.”
  • CFO on gross margin and mix: Pro forma adj gross margin rose 80 bps YoY; M6 discontinuation and productivity helped, partially offset by unfavorable geography mix due to higher international spine/biologics .

Q&A Highlights

  • Q4 implied deceleration vs Q3: CFO pointed to tough prior‑year comp as the main factor; guidance set “appropriately” .
  • 2027 CAGR cadence: Growth weighted more to 2027 driven by full Virata launch and deeper TrueLok Elevate market development .
  • U.S. spine drivers: Distributor consolidation/expansion and 7D pull‑through are the primary catalysts; top 30 distributors +25% YoY in Q3 .
  • FCF outlook: 2H positive; Q4 not at last year’s level due to forward inventory placement to support early 2026 .
  • TBT clinical validation: Company expects more clinical work/publications; growing surgeon interest around the procedure .

Estimates Context

  • Beats vs S&P Global: Revenue $205.6M vs $200.0M estimate; Primary EPS $0.20 vs (-$0.41) estimate (material beat)* .
  • S&P “EBITDA” mismatch: S&P’s GAAP EBITDA actual (-$2.65M) vs $20.2M estimate underscores the gap between GAAP EBITDA and the company’s non‑GAAP adjusted EBITDA ($25.1M), which excludes $21.5M litigation/investigation and other items .
  • Next quarter (Q4 2025) S&P consensus: revenue ~$218.7M and Primary EPS ~(-$0.22)*; management flagged comp headwinds, so models may avoid extrapolating Q3’s 6% YoY constant‑currency growth pace into Q4 .

Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Commercial execution is working: 7D‑led pull‑through plus distributor optimization are translating to above‑market U.S. spine growth (+8% net sales; +10% procedures) and expanding share pockets (lateral +24%; cervical/anterior lumbar +17%; MIS lumbar +18%) .
  • Margin trajectory remains favorable: Pro forma adj GM ~72% and seventh straight quarter of adjusted EBITDA margin expansion; FY25 EBITDA guide raised at the low end to $84–$86M .
  • Non‑GAAP vs GAAP optics matter: Large litigation/investigation charges ($21.5M) depressed GAAP metrics (e.g., GAAP EBITDA), but adjusted EBITDA rose to $25.1M; expect investor focus on the sustainability of adjustments and litigation cadence .
  • Orthopedics catalyst: TrueLok Elevate’s full launch is driving double‑digit U.S. Ortho growth (+19%); look for market development and clinical validation updates to sustain momentum .
  • FY25 setup: Midpoint net sales unchanged, but EBITDA raised; Q4 moderation vs Q3 reflects comp dynamics rather than deterioration; watch execution vs ~$219M implied Q4 pro forma revenue .
  • Liquidity/FCF: 2H positive FCF intact; near‑term cash dipped modestly to $65.9M ahead of planned inventory placement to support 2026 .
  • 2026–2027 pipeline: Virata full launch in 2027 and growing 7D footprint support management’s 6.5%–7.5% 2025–2027 net sales CAGR target framework (implied by LT plan commentary) .

Appendix: Additional Details and Cross-References

  • Q3 revenue composition and growth rates are detailed in the 8‑K/press release tables (segment pro forma, M6 impact) .
  • GAAP P&L and balance sheet: Q3 net loss $(22.8)M; diluted EPS $(0.57); cash/cash equivalents/restricted $65.9M .
  • Adjustments and reconciliations: Non‑GAAP bridges for adjusted gross profit, adjusted EBITDA, and adjusted net income are provided in the press release/8‑K .
  • Prior quarters for trend: Q2 2025 pro forma net sales $200.7M, adjusted EBITDA $20.6M; Q1 2025 pro forma net sales $189.2M, adjusted EBITDA $11.4M .